Mersana Therapeutics, Inc. (NASDAQ:MRSN) is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment. As a company listed on the NASDAQ, Mersana is preparing to release its quarterly earnings on November 14, 2025.

Wall Street anticipates an earnings per share (EPS) of -$1.44 and revenue of approximately $14.2 million. Mersana's financial metrics reveal its current challenges. The company has a price-to-earnings (P/E) ratio of -0.60, indicating it is not profitable. This aligns with the expected negative EPS. The price-to-sales ratio of 1.27 suggests investors are paying $1.27 for every dollar of sales, reflecting cautious investor sentiment. The enterprise value to sales ratio is -0.35, showing a negative enterprise value relative to sales.

However, the enterprise value to operating cash flow ratio of 0.15 indicates a relatively low valuation compared to its cash flow, which might appeal to some investors. Mersana's earnings yield is -1.67, further highlighting its lack of profitability. Despite this, the debt-to-equity ratio of -0.39 suggests the company has more equity than debt, which can be a positive sign of financial stability. The current ratio of 1.35 indicates Mersana has enough liquidity to cover its short-term liabilities, providing some reassurance to investors.